Literature DB >> 22366591

Bevacizumab rechallenge after first line maintenance bevacizumab.

Panagiotis A Konstantinopoulos, Suzanne T Berlin, Susana M Campos, Ursula A Matulonis, Stephen A Cannistra.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22366591     DOI： 10.1016/j.ygyno.2012.02.013

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  2 in total

Review 1.  Drug rechallenge and treatment beyond progression--implications for drug resistance.

Authors:  Elizabeth A Kuczynski; Daniel J Sargent; Axel Grothey; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2013-09-03       Impact factor: 66.675

2.  Bevacizumab plus chemotherapy continued beyond progression in patients with type II endometrial cancer previously treated with bevacizumab plus chemotherapy: A case report.

Authors:  Emi Sato; Kentaro Nakayama; Kohei Nakamura; Tomoka Ishibashi; Hiroshi Katagiri; Masako Ishikawa; Satoru Kyo
Journal:  Mol Clin Oncol       Date:  2017-07-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.